Novo Nordisk's GLP-1 Victoza Off To A Good Start
New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.
New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.